Antibody production: Polyclonal-derived biotherapeutics

Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences

Volumn 848, Issue 1, 2007, Pages 2-7

  Newcombe, Claire ^a   Newcombe, Anthony R ^a  

^a BIOCOMPATIBLES UK LTD   (United Kingdom)

Author keywords

Antibody; Hyperimmune; Immunization; Polyclonal; Serum; Therapeutic

Indexed keywords

ANTIBODY PRODUCTION; BIOTHERAPEUTICS; IMMUNOGLOBULINS; INFECTIONS; POLYCLONAL ANTIBODIES; TOXIN NEUTRALIZATION;

CHEMOTHERAPY; DISEASES; PURIFICATION; TOXICITY;

MONOCLONAL ANTIBODIES;

BAYGAM; BAYRAB; BAYTET; CROFAB; CYTOMEGALOVIRUS ANTIBODY; DIGOXIN ANTIBODY F(AB) FRAGMENT; DIPHTHERIA ANTIBODY; HEPATITIS B ANTIBODY; IMMUNOGLOBULIN ANTIBODY; LYMPHOCYTE ANTIBODY; LYMPHOGLOBULINE; MONOCLONAL ANTIBODY; POLYCLONAL ANTIBODY; POLYCLONAL IMMUNOGLOBULIN G; RABIES IMMUNOGLOBULIN; RECOMBINANT ANTIBODY; RECOMBINANT POLYCLONAL ANTIBODY; RESPIRATORY SYNCYTIAL VIRUS ANTIBODY; SNAKE VENOM ANTISERUM; TETANUS ANTIBODY; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG; VENOM ANTISERUM; VIPERATAB;

ANTIBODY PRODUCTION; ANTIGEN SPECIFICITY; ARTIFICIAL CHROMOSOME; CANCER; CHEMOTHERAPY; CYTOMEGALOVIRUS INFECTION; DEFENSE MECHANISM; DIPHTHERIA; DRUG INTOXICATION; DRUG SYNTHESIS; ENVENOMATION; GENETIC DISORDER; HEPATITIS A; HEPATITIS B; HUMORAL IMMUNE DEFICIENCY; IMMUNE DEFICIENCY; ISOTOPE LABELING; PRIORITY JOURNAL; PROPHYLAXIS; RABIES; RESPIRATORY TRACT INFECTION; REVIEW; SNAKE; SNAKEBITE; TETANUS; TRANSGENICS; TREATMENT PLANNING;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY FORMATION; HUMANS; IMMUNE SERA; IMMUNOTHERAPY; MODELS, THEORETICAL;

ARANEAE;

EID: 33947136435     PISSN: 15700232     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jchromb.2006.07.004     Document Type: Review

References (45)

1. Kuby J. Immunology. second ed. (1994), W.H. Freeman and Company, New York
2. Stewart A.J., and Devlin P.M. J. Infect. (2005) (Epub ahead of print)
3. Katscher F. Nature 381 (1996) 468
4. Bonnabeau R.C. Minn. Med. 66 (1983) 331
5. Casadevall A., and Scharff M.D. Clin. Infect. Dis. 21 (1995) 150
6. Casadevall A., and Scharff M.D. Antimicrob. Agents Chemother. 38 (1994) 1695
7. Lucchesi P.F., and Gildersleeve N. JAMA 116 (1941) 1506
8. Tacket C.O., Shandera W.X., Mann J.M., Hargrett N.T., and Blake P.A. Am. J. Med. 76 (1984) 794
9. Cresswell C., Newcombe A.R., Davies S., Macpherson I., Nelson P., O'donovan K., and Francis R. Biotechnol. Appl. Biochem. 42 Pt 2 (2005) 163
10. P. Kumpalume, R. Boushaba, R.G.A. Jones, N.K.H. Slater, Trans. IChemE Part C, 80, 88.
11. Hansen M.B., Lihme A., Spitali M., and King D. Bioseparation 8 (1999) 189
12. Clark R.F., McKinney P.E., Chase P.B., and Walter F.G. Ann. Emerg. Med. 39 (2002) 671
13. Dart R.C., Seifert S.A., Carroll L., Clark R.F., Hall E., Boyer-Hassen L.V., Curry S.C., Kitchens C.S., and Garcia R.A. Ann. Emerg. Med. 30 (1997) 33
14. Bara V. Emerg. Nurse 9 (2001) 16
15. Safadi R., Levy I., Amitai Y., and Caraco Y. Arch. Intern. Med. 23 155 (1995) 2121
16. Farshid M., Taffs R.E., Scott D., Asher D.M., and Brorson K. Curr. Opin. Biotechnol. 16 (2005) 561
17. Buchacher A., and Iberer G. Biotechnol. J. 1 (2006) 148
18. International Conference on Harmonisation of Technical Requirements for Registration of Pharamceuticals for Human Use: Viral Safety Evaluation of Biotechnology Products Derived from Cell Lines of Human or Animal Origin. (ICH) 5QA (R1), 1997.
19. Smith T.W. Review of clinical experience with digoxin immune Fab (ovine). Am. J. Emerg. Med. 9 2 Suppl. 1 (1991) 1-6 [Discussion 33-34]
20. Schier J.G., Wiener S.W., Touger M., Nelson L.S., and Hoffman R.S. Ann. Emerg. Med. 41 (2003) 391
21. A new snake antivenom. Med. Lett. Drugs Ther. 43 (1107) (2001) 55-56.
22. Juckett G., and Hancox J.G. Am. Fam. Physician 65 (2002) 1367
23. Lemieux R., Bazin R., and Neron S. Mol. Immunol. 42 (2005) 839
24. Durandy A., Wahn V., Petteway S., and Gelfand E.W. Int. Arch. Allergy Immunol. 136 (2005) 217
25. Martin T.D. Int. Immunopharmacol. 6 (2006) 517
26. Looney R.J., and Huggins J. Best Pract. Res. Clin. Haematol. 19 (2006) 3
27. Jolles S., Sewell W.A., and Misbah S.A. Clin. Exp. Immunol. 142 (2005) 1
28. Ballow M. Am. J. Health Syst. Pharm. 62 (2005) S12
29. Prosniak M., Faber M., Hanlon C.A., Rupprecht C.E., Hooper D.C., and Dietzschold B. J. Infect. Dis. 188 1 (2003) 53 (Epub 2003 Jun 23)
30. Song Y.Q., Wang G.F., Dai X.L., and Xie H. Cell Res. 8 (1998) 241
31. Medicines Control Agency. Rules and Guidance for Pharmaceutical Manufacturers and Distributors (2002), TSO Press, Norwich, UK
32. FDA Code of Federal Regulations (CFR), Title 21 Food and Drugs, National Archives and Records Administration, Office of the Federal Register, USA, 2004.
33. Haurum J.S., and Bregenholt S. IDrugs 8 (2005) 404
34. Robl J.M., Kasinathan P., Sullivan E., Kuroiwa Y., Tomizuka K., and Ishida I. Theriogenology 59 (2003) 107
35. Kuroiwa Y., Kasinathan P., Choi Y.J., Naeem R., Tomizuka K., Sullivan E.J., Knott J.G., Duteau A., Goldsby R.A., Osborne B.A., Ishida I., and Robl J.M. Nat. Biotechnol. 9 (2002) 889
36. Therapeutic Human Polyclonals Inc. http://www.polyclonals.com.
37. Origen Therapeutics Inc. http://www.origentherapeutics.com.
38. Casadevall A., and Pirofski L.A. Expert Opin. Biol. Ther. 5 (2005) 1359
39. Bregenholt S., and Haurum J. Expert Opin. Biol. Ther. 3 (2004) 387
40. Casadevall A. Emerg. Infect. Dis. 8 (2002) 833
41. Zagury D., and Gallo R.C. Drug. Discov. Today 9 (2004) 72
42. Neovacs SA, http://www.neovacs.com.
43. Currie G.A. Br. J. Cancer 26 (1972) 141
44. Rosenberg S.A., and Terry W.D. Adv. Cancer Res. 25 (1977) 323
45. Sharon J., Liebman M.A., and Williams B.R. J. Cell Biochem. 96 (2005) 305